
LVTX
LAVA Therapeutics NV
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.550
Open
1.5392
VWAP
1.54
Vol
78.85K
Mkt Cap
40.25M
Low
1.520
Amount
121.27K
EV/EBITDA(TTM)
--
Total Shares
26.29M
EV
-26.31M
EV/OCF(TTM)
--
P/S(TTM)
--
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
0.00
-100%
--
--
Estimates Revision
Stock Price
Go Up

+22.40%
In Past 3 Month
3 Analyst Rating

-10.46% Downside
Wall Street analysts forecast LVTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LVTX is 1.37 USD with a low forecast of 1.24 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold

-10.46% Downside
Current: 1.530

Low
1.24
Averages
1.37
High
1.50

-10.46% Downside
Current: 1.530

Low
1.24
Averages
1.37
High
1.50
Jefferies
Buy
to
Hold
downgrade
$3
2025-08-05
Reason
Jefferies
Price Target
$3
2025-08-05
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Lava Therapeutics (LVTX) to Hold from Buy with a price target of $1.50, down from $3, after the company entered into an agreement to be acquired by XOMA Royalty (XOMA) for between $1.16 and $1.24 per share in cash.
HC Wainwright & Co.
Arthur He
Hold
Reiterates
$1.5
2025-03-31
Reason
HC Wainwright & Co.
Arthur He
Price Target
$1.5
2025-03-31
Reiterates
Hold
Reason
HC Wainwright & Co.
Arthur He
Strong Buy
to
Hold
Downgrades
$2 → $1.5
2025-02-27
Reason
HC Wainwright & Co.
Arthur He
Price Target
$2 → $1.5
2025-02-27
Downgrades
Strong Buy
to
Hold
Reason
HC Wainwright & Co.
Arthur He
Strong Buy
Maintains
$6 → $2
2024-12-20
Reason
HC Wainwright & Co.
Arthur He
Price Target
$6 → $2
2024-12-20
Maintains
Strong Buy
Reason
Leerink Partners
Daina Graybosch
Buy
to
Hold
Downgrades
$11 → $2
2024-12-12
Reason
Leerink Partners
Daina Graybosch
Price Target
$11 → $2
2024-12-12
Downgrades
Buy
to
Hold
Reason
Leerink analyst Daina Graybosch downgraded Lava Therapeutics to Market Perform from Outperform with a price target of $2, down from $11, following the company's discontinuation of LAVA-1207, which was in Phase 1 development for metastatic castration-resistant prostate cancer. The firm acknowledges several valid prostate cancer-related challenges that may not necessarily read through to other targets and indications. That said, Leerink finds it difficult to give its platform the benefit of the doubt.
JMP Securities
Reni Benjamin
Buy
to
Hold
Downgrades
$6
2024-12-11
Reason
JMP Securities
Reni Benjamin
Price Target
$6
2024-12-11
Downgrades
Buy
to
Hold
Reason
JMP Securities analyst Reni Benjamin downgraded Lava Therapeutics to Market Perform from Outperform without a price target following the Q3 report. The firm citers a lack of near-term milestones for the downgrade. With LAVA-1207 discontinued, LAVA-1266 Phase 1 underway, and a cash position of $78.9MM, the shares are fairly valued, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for LAVA Therapeutics NV (LVTX.O) is -1.51, compared to its 5-year average forward P/E of -2.02. For a more detailed relative valuation and DCF analysis to assess LAVA Therapeutics NV 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.02
Current PE
-1.51
Overvalued PE
-0.71
Undervalued PE
-3.34
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.32
Undervalued EV/EBITDA
-1.96
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
104.31
Current PS
0.00
Overvalued PS
313.57
Undervalued PS
-104.95
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+272.69%
-7.59M
Operating Profit
FY2025Q1
YoY :
+472.20%
-3.48M
Net Income after Tax
FY2025Q1
YoY :
+550.00%
-0.13
EPS - Diluted
FY2025Q1
YoY :
+1244.69%
-11.65M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
+130.72%
-608.14
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LVTX News & Events
Events Timeline
2025-08-13 (ET)
2025-08-13
16:58:15
Lava Therapeutics reports Q2 EPS (32c) vs. (31c) last year

2025-08-04 (ET)
2025-08-04
07:40:39
Xoma to acquire Lava Therapeutics for $1.16-$1.24 per share in cash plus CVR

2025-05-14 (ET)
2025-05-14
07:33:05
Lava Therapeutics reports Q1 EPS (13c) vs (2c) last year

Sign Up For More Events
Sign Up For More Events
News
9.5
08-13NewsfilterPinnedLAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
7.0
08-08PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders
4.0
08-05BenzingaHC Wainwright & Co. Maintains Neutral on LAVA Therapeutics, Lowers Price Target to $1.24
Sign Up For More News
People Also Watch

PRZO
Parazero Technologies Ltd
1.590
USD
+3.92%

HUDI
Huadi International Group Co., Ltd.
1.130
USD
+2.73%

KFFB
Kentucky First Federal Bancorp
3.100
USD
-2.33%

CKX
CKX Lands Inc
11.660
USD
-0.77%

LRE
Lead Real Estate Co Ltd
1.580
USD
+3.27%

BNAI
Brand Engagement Network Inc
0.311
USD
-2.51%

MXC
Mexco Energy Corp
8.200
USD
-2.73%

GFAI
Guardforce AI Co Ltd
1.210
USD
+6.61%

PLUR
Pluri Inc
4.860
USD
+2.53%
FAQ

What is LAVA Therapeutics NV (LVTX) stock price today?
The current price of LVTX is 1.53 USD — it has increased 0 % in the last trading day.

What is LAVA Therapeutics NV (LVTX)'s business?

What is the price predicton of LVTX Stock?

What is LAVA Therapeutics NV (LVTX)'s revenue for the last quarter?

What is LAVA Therapeutics NV (LVTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for LAVA Therapeutics NV (LVTX)'s fundamentals?

How many employees does LAVA Therapeutics NV (LVTX). have?
